Product Description
The research-grade biosimilar is a fully human IgG1 monoclonal antibody that binds to the vascular endothelial growth factor receptor 2 (VEGFR2) and inhibits association with its ligands (VEGF A, C, and D). This prevents VEGF-mediated proliferation, migration of endothelial cells, and angiogenesis. The original monoclonal antibody received FDA approval to treat advanced gastric cancer/gastro-esophageal junction (GEJ) adenocarcinoma. It is also approved for use for the combination treatment of metastatic non-small lung carcinoma (NSLC), metastatic colorectal cancer (mCRC), and hepatocellular carcinoma (HCC).
Biovision | A2139 | Anti-VEGFR2 (Ramucirumab), Human IgG1 Antibody DataSheet
Antibody Target: VEGFR2
Target Alternative Name: FLK1, CD309, VEGFR, VEGFR2, KDR
Tag Line: A fully human monoclonal antibody that inhibits the association of VEGFR2 with its ligands and prevents VEGF-mediated tumor angiogenesis
Category: Biosimilars
Host: Human
Isotype: IgG1, kappa
Species Reactivities: Human
Immunogen Sequence: Ramucirumab
Accession #: DB05578
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: Lot specific
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application: In vitro studies
Positive Control:
Application And Usages: In vitro studies
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE